Mergers and Acquisitions Negotiation Pharmaceutical 
How2Exit
MARCH 31, 2024
Get the Insider Tips You Need to Secure Your Deal - Watch Here rn rn About the Guest(s): rn Patrick O'Connell is an experienced mergers and acquisitions (M&A) advisor with a profound depth of knowledge in buying and selling small businesses valued between one to $20 million. b' E200: Buying or Selling a Small Business?
Devensoft
MAY 25, 2023
Corporate restructuring can be a game-changer for any organization, whether it’s a merger, acquisition, or any other strategic move. From identifying the right targets to negotiating deals and integrating teams, there are several critical steps involved in executing a successful restructuring plan.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Cooley M&A
OCTOBER 24, 2024
Alexion Pharmaceuticals (Del. September 2024), the Delaware Chancery Courts found buyers liable for failure to comply with negotiated earnout covenants – and in the latter case, awarded the plaintiffs more than $1 billion in damages. In both Fortis v. Johnson & Johnson (Del. September 2024) and SRS v.
Cooley M&A
FEBRUARY 8, 2018
No longer just “acquihires,” today’s innovation-driven acquisition is focused on talent retention. One familiar technique used by sophisticated tech buyers is a holdback structure that subjects a portion of key employees’ merger consideration to revesting. The typical revesting period for these arrangements is 24 to 36 months.
Sun Acquisitions
AUGUST 22, 2024
To mitigate these risks and build more resilient supply chains, companies are increasingly turning to strategic mergers and acquisitions (M&A). Larger, consolidated companies can negotiate better terms with suppliers, secure more favorable contracts, and reduce per-unit production costs.
Cooley M&A
OCTOBER 29, 2018
M&A practitioners have long advised boards of directors that the Delaware courts have never found that the events or circumstances in a particular transaction met the contractual standard of having a material adverse effect (or MAE) as defined in a merger or acquisition agreement. The Merger Agreement. 2018-0300-JTL (Del.
Cooley M&A
JANUARY 25, 2023
But it wasn’t all carve outs and concerned investors – even with the headwinds in the industry and beyond, there were still several traditional public M&A deals involving biotechnology or medical device companies, as large pharmaceutical companies continued to have cash to deploy for acquisitions.
Expert insights. Personalized for you.
130 
Let's personalize your content